1352879-52-7
Chemical Structure
Sarafloxacin-d8
Synonym(s): A-56620-d8
- CAS No.: 1352879-52-7
- Formula:C20H9D8F2N3O3
- Molecular Weight:393.41
IUPAC Name: tert-butyl (2S,3S)-2-amino-3-methylpent-4-enoate
InChIKey: XBHBWNFJWIASRO-YEBVBAJPSA-N
SMILES: O=C(C1=CN(C2=CC=C(F)C=C2)C3=C(C=C(F)C(N4C([2H])([2H])C([2H])([2H])NC([2H])([2H])C4([2H])[2H])=C3)C1=O)O
Biological Activity: Sarafloxacin-d8 (A-56620-d8) is the d8 labeled Sarafloxacin (HY-B0343). Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sarafloxacin-d8 | Sarafloxacin-d8 (A-56620-d8) is the d8 labeled Sarafloxacin (HY-B0343). Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarafloxacin (Standard) | ≥98% | Sarafloxacin (Standard) (A-56620 (Standard)) is the analytical standard of Sarafloxacin (HY-B0343). This product is intended for research and analytical applications. Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sarafloxacin | Sarafloxacin (A-56620) is a fluoroquinolone Antibacterial agent. Sarafloxacin inhibits the growth of Staphylococcus aureus, Enterobacteriaceae, and both aminoglycoside-sensitive and aminoglycoside-resistant strains of Pseudomonas aeruginosa. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. McConville ML, et al. Effects of sarafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. Vet Q. 1995;17(1):1-5. [Content Brief]
- [2]. Fernandes CJ, et al. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates. Chemotherapy. 1988;34(3):216-228. [Content Brief]
